AA amyloidosis treated with tocilizumab: case series and updated literature review. (Q38317176)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

review article

1 reference

title

AA amyloidosis treated with tocilizumab: case series and updated literature review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Éric Hachulla

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Alice Courties

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Gilles Grateau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Peggy Philippe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

René-Marc Flipo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Bérengère Aubry-Rozier

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Isabelle Fabreguet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Wafki Fahd

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Olivier Fain

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Pascal Guggenbuhl

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Thomas Papo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Christophe Richez

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jean Sibilia

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jacques Morel

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Francis Berenbaum

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jérémie Sellam

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Club Rhumatismes Inflammation and the REGATE Registry

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

14 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

84-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

Molecular mechanisms of amyloidosis

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Amyloidosis in autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Treatment of AA amyloid with chlorambucil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Eprodisate for the treatment of renal disease in AA amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Renal amyloidosis secondary to rheumatoid arthritis: remission of proteinuria and renal function improvement with tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Successful use of Tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

Do inflammatory rheumatic diseases still cause as much harm through amyloidosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2014.1002031

10.3109/13506129.2014.1002031

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585627%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference